Milestone Pharmaceuticals
A North American biopharma company focused on the development and commercialization of cardiovascular medicines.
Milestone's lead product candidate, etripamil, is currently in a Phase III program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase II proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate.
In October 2022, Milestone announced positive top-line efficacy and safety data from the Phase III RAPID clinical trial of etripamil in PSVT.
Latest Milestone Pharmaceuticals News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze